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Objectives The purpose of this research was to perform a feasibility study of prophylactic coronary revascularization in pa-
tients with preoperative extensive stress-induced ischemia.
Background Prophylactic coronary revascularization in vascular surgery patients with coronary artery disease does not im-
prove postoperative outcome. If a beneficial effect is to be expected, then at least those with extensive coronary
artery disease should benefit from this strategy.
Methods One thousand eight hundred eighty patients were screened, and those with 3 risk factors underwent cardiac
testing using dobutamine echocardiography (17-segment model) or stress nuclear imaging (6-wall model). Those
with extensive stress-induced ischemia (5 segments or 3 walls) were randomly assigned for additional revas-
cularization. All received beta-blockers aiming at a heart rate of 60 to 65 beats/min, and antiplatelet therapy
was continued during surgery. The end points were the composite of all-cause death or myocardial infarction at
30 days and during 1-year follow-up.
Results Of 430 high-risk patients, 101 (23%) showed extensive ischemia and were randomly assigned to revasculariza-
tion (n  49) or no revascularization. Coronary angiography showed 2-vessel disease in 12 (24%), 3-vessel dis-
ease in 33 (67%), and left main in 4 (8%). Two patients died after revascularization, but before operation,
because of a ruptured aneurysm. Revascularization did not improve 30-day outcome; the incidence of the com-
posite end point was 43% versus 33% (odds ratio 1.4, 95% confidence interval 0.7 to 2.8; p  0.30). Also, no
benefit during 1-year follow-up was observed after coronary revascularization (49% vs. 44%, odds ratio 1.2,
95% confidence interval 0.7 to 2.3; p  0.48).
Conclusions In this randomized pilot study, designed to obtain efficacy and safety estimates, preoperative coronary revascu-
larization in high-risk patients was not associated with an improved outcome. (J Am Coll Cardiol 2007;49:
1763–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.052r
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Patients with multiple cardiac risk factors
scheduled for major vascular surgery are at
increased risk of perioperative cardiac compli-
cations. According to the guidelines of the
American College of Cardiology/American
Heart Association (ACC/AHA), it is highly
rom the Departments of *Anesthesiology, †Vascular Surgery, ‡Cardiology, and
Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands;
Department of Cardiology, Leiden University Medical Center, Leiden, the Neth-
rlands; and the Department of Anesthesiology, University of Alberta, Winnipeg, aecommended to refer these patients for noninvasive cardiac
tress testing before surgery (1). The guidelines also recom-
end coronary angiography for patients with high-risk
See page 1770
anitoba, Canada. Members of the DECREASE Study Group are listed in the
ppendix. Kim Eagle, MD, acted as the Guest Editor for this article.
Manuscript received July 19, 2006; revised manuscript received October 31, 2006,
ccepted November 2, 2006.
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Revascularization Before Noncardiac Surgery May 1, 2007:1763–9noninvasive test results, and myo-
cardial revascularization in pa-
tients with prognostic high-risk
anatomy in whom long-term
outcome is likely to be improved.
However, noninvasive testing
may delay surgery and run the
risk of aortic aneurismal rupture
or exacerbation of critical limb
ischemia. Furthermore, coronary
revascularization is commonly
performed by percutaneous coro-
nary intervention (PCI) with stent
placement instead of bypass sur-
gery (CABG). Although this ap-
proach prevents further delay of
he index surgical procedure, it necessitates the prolonged
se of extensive antiplatelet therapy, which may aggravate
he risk of perioperative bleeding complications. But tem-
orary discontinuation of antiplatelet therapy is potentially
armful, as it may lead to in-stent thrombosis (2,3).
The current ACC/AHA recommendations are based on
mall observational, noncontrolled studies and expert opin-
on (4,5). The usefulness of the strategy of prophylactic
evascularization was not confirmed by the recently com-
leted CARP (Coronary Artery Revascularization Prophy-
axis) randomized trial (6). In this trial, the incidence of
erioperative myocardial infarction was similar in patients
llocated to prophylactic revascularization versus those allo-
ated to optimal medical therapy (12% vs. 14% events).
here was also no beneficial effect observed during long-
erm follow-up. However, it should be realized that the vast
ajority of patients included in the CARP trial had single-
r 2-vessel disease with a preserved left ventricular function.
ndeed, based on previous research from our group, suffi-
ient cardioprotection by medical therapy can be expected in
hese patients, which may explain the CARP trial findings
7). In contrast, patients with multiple cardiac risk factors
nd extensive stress-induced myocardial ischemia are insuf-
ciently protected (7).
Hence, if a beneficial effect of the invasive strategy of
rophylactic revascularization is to be expected, then at least
atients with extensive coronary artery disease should ben-
fit from this strategy. We therefore undertook the DE-
REASE (Dutch Echocardiographic Cardiac Risk Evalu-
tion Applying Stress Echo)-V pilot study to assess the
easibility and to obtain initial efficacy and safety estimates
or the design of an adequately powered randomized con-
rolled clinical trial in these patients.
ethods
atients. This study was conducted during 2000 to 2005 in
hospitals in Belgium (until 2001), Brazil (until 2001), the
etherlands, Italy, Serbia, and Montenegro. The early
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
CABG  coronary artery
bypass graft
CI  confidence interval
LVEF  left ventricular
ejection fraction
OR  odds ratio
PCI  percutaneous
coronary interventionessation in participation to the study of 2 centers was due mo logistic reasons. A total of 1,880 consecutive patients
ndergoing elective open abdominal aortic or infrainguinal
rterial reconstruction were screened for the prevalence of
ardiac risk factors (Fig. 1). These included age over 70
ears, angina pectoris, prior myocardial infarction on the
asis of history or a finding of pathologic Q waves on
lectrocardiography, compensated congestive heart fail-
re or a history of congestive heart failure, drug therapy
or diabetes mellitus, renal dysfunction (serum creatinine
160 mol/l), and prior stroke or transient ischemic
ttack (7). Patients with at least 3 risk factors underwent
ardiac stress testing before surgery. All patients who
xperienced extensive stress-induced ischemia were en-
olled in the DECREASE-V pilot study.
All patients provided informed consent, and the study
as approved by the Erasmus Medical Center Medical
thics Committee and local research ethics committees.
ardiac testing. Left ventricular ejection fraction (LVEF)
as measured from resting echocardiographic images using
he biplane Simpson’s rule. Cardiac stress testing was
erformed by dobutamine echocardiography or dobutamine
r dipyridamole perfusion scintigraphy, as previously de-
cribed (8,9). Test results were scored by the extent of
tress-induced ischemia using a 17-segment model in do-
utamine echocardiography and a 6-wall model in stress
erfusion scintigraphy. Limited ischemia was defined by the
resence of 1 to 4 ischemic segments or 1 to 2 ischemic
alls, whereas extensive ischemia was defined by 5 isch-
mic segments or 3 ischemic walls.
llocated treatment. Perioperative beta-blocker therapy
as installed in all patients at the screening visit, regardless
f test results. A computer algorithm was used at each
enter to assign patients with extensive stress-induced isch-
mia randomly, in a 1:1 ratio, to 1 of the 2 strategies. The
ealed envelope method was used to conceal treatment
llocation, and it was assured that envelopes were opened in
onsecutive order. Patients were randomized to either an
nvasive approach followed by revascularization or a nonin-
asive approach. Quantitative analysis of all coronary an-
iographies was reviewed centrally at Erasmus Medical
enter, Rotterdam, the Netherlands, by 2 experienced
ardiologists. They assessed independently the number of
ffected vessels. The mode of revascularization, CABG or
CI with stenting, was decided by the treating physicians,
ased on coronary anatomy and the possible delay of the
ndex surgical procedure. Patients allocated to the medical-
nly strategy were referred for surgery without further delay.
eta-blocker therapy. Patients on chronic beta-blocker
herapy continued their medication. Patients without beta-
lockers started with bisoprolol 2.5 mg once a day at the
creening visit. Beta-blocker dose was adjusted in all pa-
ients at admission to the hospital and on the day before
urgery to achieve a resting heart frequency of 60 to 65
eats/min. The same dose of beta-blockers was continued
ostoperatively except in patients who were unable to take
edication orally or by nasogastric tube postoperatively. In
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May 1, 2007:1763–9 Revascularization Before Noncardiac Surgeryhese patients, the heart rate was monitored continuously at
he intensive care unit or hourly at the ward, and intrave-
ous metoprolol was administered at a dose sufficient to
eep the heart rate between 60 to 65 beats/min. The heart
ate and blood pressure were measured immediately before
ach scheduled dose of beta-blockers. Beta-blockers were
ithheld if the heart rate was 50 beats/min or the systolic
lood pressure was 100 mm Hg. After discharge, patients
ontinued beta-blocker therapy, and dose adjustments were
arried out during outpatient visits to achieve a resting heart
requency of 60 to 65 beats/min.
erioperative management. Anesthetic management,
onitoring, and other aspects of perioperative management
ere at the discretion of the attending physician. Results of
reoperative testing and coronary revascularization were
iscussed with the attending physicians, and hemodynamic
anagement was implemented accordingly. Anticoagulant
nd antiplatelet therapy was continued after PCI and during
he index surgical procedure. Intraoperative ischemia was
reated at the discretion of attending physicians, and addi-
Figure 1 Flowchart of the Study
Cardiac risk factors included age over 70 years, angina pectoris, prior myocardial
ography, compensated congestive heart failure or a history of congestive heart fai
mol/l), and prior stroke or transient ischemic attack. Patients with 3 risk factoional beta-blockers were permitted. and point definition. All patients were monitored for
ardiac events after screening. Twelve-lead electrocardio-
ram (ECG) and serum troponin-T level were systemati-
ally determined 1, 3, 7, and 30 days after surgery. Outpa-
ient follow-up was performed at 30 days if a patient had
een discharged from the hospital. At the outpatient clinic,
ll patients were screened at 3-month intervals for cardiac
vents by clinical history and 12-lead ECG. All data were
ollected by the participating centers and evaluated in a
linded fashion by members of the adverse-events commit-
ee. The primary end point was the composite of all-cause
eath and nonfatal myocardial infarction that occurred
etween screening and 30-days after the index surgical
rocedure. Patients were followed-up during at least 1 year
fter surgery, and the composite of all-cause death and
onfatal myocardial infarction during this period was con-
idered as secondary end point. Myocardial infarction
ithin 48 h after CABG was defined as a creatine kinase
CK)-MB rise above 5 the local upper limit of normal.
yocardial infarction within 48 h after PCI was defined as
ion (MI) on the basis of history or a finding of pathologic Q waves on electrocardi-
rrent treatment for diabetes mellitus, renal dysfunction (serum creatinine 160
extensive ischemia were randomly (1:1) assigned to coronary revascularization.infarct
lure, cu
rs andCK-MB rise above 3 the upper limit of normal.
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Revascularization Before Noncardiac Surgery May 1, 2007:1763–9yocardial infarction within 30 days after the index surgical
rocedure was defined as a positive troponin-T level in
ombination with new Q waves on the ECG lasting more
han 0.03 s. In all other situations, myocardial infarctions
ere defined by new Q waves lasting more than 0.03 s.
ample size. The purpose of this pilot study was to assess
he feasibility of prophylactic revascularization in high-risk
atients scheduled for major vascular surgery, and to obtain
nitial efficacy and safety estimates needed for the design of
n adequately powered randomized controlled clinical trial.
e aimed for the enrollment of 100 patients, 50 in each
trategy. Based on the DECREASE-I study (7), an
ncidence of 33% of the primary end point was expected
n the patients allocated to optimal medical therapy only.
t was recognized a priori that a modest, but clinically
elevant, risk reduction by prophylactic revascularization
ould not be detectable given this sample size. However,
f the beneficial effect of revascularization was similar to
he observations in the CASS (Coronary Artery Surgery
tudy) registry (85% risk reduction associated with prior
ABG in vascular surgery), then our study has 93%
ower (type II error of 7%), based on a 2-sided test with
type I error of 5%.
tatistical analysis. All analyses were based on the
ntention-to-treat principle. Continuous data are presented
s median values and corresponding 25th and 75th percen-
iles, whereas dichotomous data are presented as percent-
ges. Differences in clinical and surgical characteristics
etween patients allocated to revascularization or no revas-
ularization were evaluated by Wilcoxon nonparametric
ests, chi-square tests, or Fisher exact tests, as appropriate.
ifferences in the incidence of the end points were evalu-
ted by a chi-square test. The incidence of events over time
as further examined by the Kaplan-Meier method,
hereas a log-rank test was applied to evaluate differences
etween the allocated treatment strategies. Analyses were
erformed according to the intention-to-treat principle. All
tatistical tests were 2-sided, and a p value 0.05 was
onsidered significant.
esults
haracteristics of patients. A total of 1,880 vascular
urgery patients were enrolled and screened for cardiac risk
actors (Fig. 1), and 430 (23%) were classified as high risk,
ho were referred for cardiac testing. Testing showed
xtensive ischemia in 101 (22%). Dobutamine echocardiog-
aphy was performed in 88 (88%), and stress scanning in 13
13%). No serious side effects occurred during stress testing.
f 101 patients with extensive stress-induced ischemia, 49
atients were randomized for coronary revascularization. A
educed LVEF (35%) was observed in 43 (43%) patients.
o patient had significant valve disease such as aortic
tenosis or mitral valve regurgitance. Coronary angiography,
erformed in patients allocated to the invasive strategy,
howed 2-vessel disease in 12 (24%), 3-vessel disease in 33 u67%), and left main disease in 4 (8%). A PCI was
erformed in 32 patients, using a drug-eluting stent in 30
nd a bare-metal stent in 2, and bypass surgery in 17. There
ere no differences in the presence of ischemic heart disease
i.e., previous myocardial infarction and angina pectoris) or
ther baseline characteristics between the randomized
roups (Table 1). Complete revascularization was achieved
n 42 (86%). Incomplete revascularization occurred in
(15%) patients initially scheduled for a percutaneous
ntervention. Bypass surgery was considered not feasible in
hese patients as the index procedure could not be further
elayed. The median duration of revascularization to oper-
tion was 29 (13 to 65) days in the 17 patients undergoing
ypass surgery and 31 (19 to 39) days in the 32 patients
ndergoing a percutaneous intervention.
Antiplatelet therapy, using aspirin and clopidogrel, was
ontinued during surgery in all patients who underwent a
CI. The median perioperative blood transfusion require-
ent in patients with and without antiplatelet therapy was
imilar: 2 versus 3 U (p value  0.25).
erioperative cardiac events. Two patients died before
ascular surgery because of a ruptured aneurysm after
uccessful bypass surgery. Their aortic diameters were,
espectively, 62 and 73 mm. In 1 patient, a myocardial
nfarction occurred after an incomplete coronary revas-
ularization. This precluded the proceeding of the sched-
aseline Characteristics
Table 1 Baseline Characteristics
Revascularization No Revascularization
Number of patients 49 52
Age (yrs) 71 (64, 74) 70 (63, 75)
Men 42 (86%) 47 (90%)
History of diabetes 18 (37%) 15 (29%)
Current angina pectoris 25 (51%) 22 (42%)
History of myocardial infarction 49 (100%) 50 (96%)
History of congestive heart failure 23 (47%) 24 (46%)
History of cerebrovascular accident 20 (41%) 13 (25%)
History of renal failure 9 (18%) 11 (21%)
Aspirin use 37 (76%) 30 (58%)
Beta-blocker use 34 (70%) 36 (69%)
ACE inhibitor use 28 (57%) 22 (42%)
Statin use 34 (69%) 30 (58%)
Type of surgery
Thoraco-abdominal 5 (10%) 5 (10%)
Tube graft 11 (22%) 14 (27%)
Bifurcated graft 10 (20%) 15 (29%)
Femoro-popliteal 23 (47%) 18 (35%)
Right coronary artery disease 39 (80%) —
Left artery descending 46 (94%) —
Left circumflex artery 37 (76%) —
Number of diseased vessels —
1 0 —
2 12 (24%) —
3 33 (67%) —
Left main disease (%) 4 (8%) —
CE  angiotensin-converting enzyme.led vascular surgery. Revascularization did not improve
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May 1, 2007:1763–9 Revascularization Before Noncardiac Surgery0-day outcome after vascular surgery. Troponin eleva-
ion was found in 38.8% in the noninvasive group versus
4.7% in the invasive group. The incidence of all-cause
eath or nonfatal myocardial infarction for patients with
reoperative revascularization or medical treatment only
as 43% versus 33%, respectively (odds ratio [OR] 1.4,
5% confidence interval [CI] 0.7 to 2.8; p  0.30)
Table 2). Also, no difference was observed in the incidence of
erioperative cardiac events between patients treated by pro-
hylactic bypass surgery or percutaneous intervention (41.1%
s. 43.8%, respectively).
ate cardiac events. The incidence of the 1-year end point
ll-cause death or nonfatal myocardial infarction in high-
isk patients was 47%. In high-risk patients, no long-term
Patient Outcome
Table 2 Patient Outcome
Revascularizatio
n (%)
Number of patients 49
Events before surgery
All-cause mortality 2 (4.1)
Myocardial infarction 1 (2.1)
Composite 3 (6.1)
Events up to 30 days after surgery
All-cause mortality 11 (22.5)
Myocardial infarction 17 (34.7)
Composite 21 (42.9)
Events up to 365 days after surgery
All-cause mortality 13 (26.5)
Myocardial infarction 18 (36.7)
Composite 24 (49.0)
CI  confidence interval; HR  hazard ratio.
Figure 2 Incidence of All-Cause Death or Myocardial Infarction
Allocated Strategy in Patients With 3 or More Cardiac
Light line  best medical treatment only; dark line  best medical treatment andenefit was observed after coronary revascularization; re-
pectively, 49% versus 44% of patients with preoperative
evascularization or medical treatment only died or experi-
nced a nonfatal myocardial infarction (OR 1.2, 95% CI 0.7
o 2.3; p  0.48) (Fig. 2). No patients initially randomized
or medical therapy underwent revascularization within 1
ear of follow-up. One patient randomized to the invasive
trategy underwent a redo PCI because of myocardial
nfarction in the first year of follow-up.
mplications for a study design. Assuming that the event
ates in the 101 studied patients are representative of what
ould occur in the planned study, the required sample size
or a randomized study to establish definitively that coro-
ary revascularization is superior to medical therapy to
No Revascularization
n (%) HR (95% CI) p Value
52
0 — 0.23
0 —
0 — 0.11
6 (11.5) 2.2 (0.74–6.6) 0.14
16 (30.8) —
17 (32.7) 1.4 (0.73–2.8) 0.30
12 (23.1) 1.3 (0.55–2.9) 0.58
19 (36.5)
23 (44.2) 1.2 (0.68–2.3) 0.48
g 1-Year Follow-Up According to the
Factors With Extensive Stress-Induced Ischemia
ylactic revascularization.nDurin
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Revascularization Before Noncardiac Surgery May 1, 2007:1763–9mprove postoperative outcome in high-risk patients by
0% (relative risk) compared to optimal medical therapy
ould be over 300 patients per arm. This would require
sample size of 9,000 major vascular surgery patients, of
hich 2,000 patients have 3 or more cardiac risk factors
t screening.
iscussion
he concept of a beneficial effect of prophylactic coronary
evascularization before major vascular surgery is based on
he assumption that perioperative myocardial infarctions
rise at locations in coronary arteries with hemodynamically
ritical stenosis, elicited by the stress of surgery. Preopera-
ive coronary revascularization might prevent this devastat-
ng event and, in addition, improve long-term outcome.
his hypothesis was supported by the CASS study that
howed a reduced incidence of nonfatal myocardial infarc-
ions after previous bypass surgery among vascular surgery
atients compared with those treated medically (8.5% vs.
.6%, p  0.001) (4). More recently, the data from the
ARI (Bypass Angioplasty Revascularization Investigation)
rial showed that bypass surgery and PCI had similar low
ates of postoperative cardiac events in noncardiac surgery
5). However, these studies were not designed to assign the
ptimal strategy in severely ill patients with extensive
oronary artery disease immediately before major vascular
urgery. In addition, these studies could not address the
oncern of delaying the vascular surgical procedure because
f testing, revascularization, and initiation of antiplatelet
herapy since the time between revascularization and non-
ardiac surgery in these studies was, respectively, 4.1 and 2.4
ears.
The randomized CARP trial was the first study that
ddressed the strategy of prophylactic revascularization
ompared with optimal medical therapy in patients with
linically stable coronary artery disease who were scheduled
or major vascular surgery (6). This trial showed that
rophylactic revascularization was safe but did not improve
erioperative or long-term outcome. The long-term mor-
ality was 22% in patients allocated to prophylactic coronary
evascularization, compared with 23% in the medical only
trategy (p  0.92). Also, the incidence of perioperative
onfatal myocardial infarction was similar, respectively, 12%
nd 14% (p  0.37). In the present study, the effect of
rophylactic revascularization was comparable to the effect
eported by McFalls et al. (6), although the study population
s different. The current study population consisted of 12%
omen, 43% of the patients had a reduced left ventricular
unction (LVEF 35%), and the vast majority of patients,
5%, had 3-vessel or left main disease compared with 33%
n the CARP trial. In a subgroup of 37 comparable patients
f the CARP trial (i.e., 3 or more cardiac risk factors and
xtensive stress-induced ischemia assessed by noninvasive
esting), prophylactic coronary revascularization was associ-
ted with a favorable, nonsignificant trend for long-term murvival (OR 4.0, 95% CI 0.8 to 19). If a beneficial effect of
evascularization was to be expected, this should have
ccurred in the selected population with high-risk anatomy.
owever, this was not observed, although the current study
as not powered to test this strategy. A study to establish
he effect of coronary revascularization would require, based
n the findings of this pilot study, a screening population of
,000 patients, of which 2,000 would have 3 or more risk
actors, and of these 600 would have extensive stress-
nduced ischemia during cardiac testing and be eligible for
andomization to revascularization. Our findings support
he current guidelines of the ACC/AHA on perioperative
anagement in high-risk patients to reserve revasculariza-
ion only for cardiac unstable patients. After successful
ascular surgery, these patients should be regularly screened
or the presence of ischemic complaints, and aggressive
nti-ischemic therapy, both medical and invasive, should be
onsidered. As shown in Figure 2, a trend was observed for
“catch up” of late cardiac events in patients treated
edically. In these patients at high risk scheduled for major
ascular surgery, prophylactic revascularization might be
witched to late revascularization, preventing the delay of
urgery.
The apparent lack of benefit of coronary revascularization
f the present study is not fully understood. Most likely,
atients with stress-induced ischemia not only suffer from a
lood flow-limiting coronary lesion but also from (multiple)
onsignificant lesions that are vulnerable to rupture due to
he stress of surgery (10). The perioperative stress response,
hich includes a cytokine response, catecholamine surge
ith associated hemodynamic stress, vasospasm, reduced
brinolytic activity, platelet activation, and consequent hy-
ercoagulability, triggers coronary plaque rupture, leading to
hrombus formation and subsequent vessel occlusion
11,12). Autopsy results have shown that this mechanism is
esponsible for at least half of all perioperative infarctions
10,12). These findings are in line with dobutamine echo-
ardiography results that show a correlation between the
ssessment of the preoperative culprit coronary lesion and
he location of the perioperative myocardial infarction in
nly half of all cases (13). Surgical or percutaneous treat-
ent of the culprit coronary lesion(s) apparently provides
nsufficient protection for rupture of these instable lesions.
The optimal perioperative evaluation and management of
atients with multiple risk factors and extensive stress-
nduced ischemia remains controversial. Success will depend
n careful collaboration between cardiologists, anesthesiol-
gists, and surgeons. In patients with aortic aneurysms, a
urgical repair is performed to reduce the chance of
neurysm-related death. It might be hypothesized that
bdominal aortic aneurysm repair should not be performed
n this high-risk group. As the current trial shows, open
epair poses an unacceptable 30-day cardiac event rate of
pproximately 30%, whereas the chance of aneurysm rup-
ure is around 9 per 100 person-years. Endovascular treat-
ent modalities may be an alternative for these high-risk
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May 1, 2007:1763–9 Revascularization Before Noncardiac Surgeryatients. Although the EVAR (Endovascular Aneurysm
epair)-2 trial showed no benefit of elective endovascular
epair in patients deemed unfit for open repair because of
omorbidities (14), these findings were not confirmed in the
ecently conducted study by the Society for Vascular Surgery
utcomes Committee. In a group of 565 high-risk patients,
atched for the EVAR-2 inclusion criteria, undergoing
ndovascular repair, perioperative mortality was 2.9%.
hese promising results need to be confirmed in a large
tudy population. Importantly, in all cases, an individualized
trategy should be performed, weighing the chances of
uture aneurysms rupture or limb salvage instead of ampu-
ation and short-term perioperative events.
onclusions
n this small randomized pilot study, designed to obtain
nitial efficacy and safety estimates for the design of an
dequately powered randomized controlled clinical trial,
reoperative coronary revascularization in high-risk vascular
urgery patients with extensive stress-induced ischemia was
ot associated with an improved postoperative and long-
erm outcome.
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